Shandong Weigao Group Medical Polymer Co Ltd (1066) Fair Value & Analysis

Healthcare · HK · Market cap HK$14.4B (≈ $1.8B) · ISIN CNE100000171

What is Shandong Weigao Group Medical Polymer Co Ltd really worth?

SW Shandong Weigao Group Medical Polymer Co Ltd 1066 · HK

PriceHK$3.27

Fair ValueHK$8.24

Upside+152.4%

Quality61/100

A solid business, trading 60% below our fair value of HK$8.24.

As of Aug 30, 2026, the fair value of Shandong Weigao Group Medical Polymer Co Ltd is HK$8.24 per share against a price of HK$3.27, so the fair value sits 152% above the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Shandong Weigao Group Medical Polymer Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Solidly profitable · 12.0% net margin

✓Low debt · generates free cash flow

✓Ranks above peers (11/15)

Risks

!Mixed Growth (revenue 5y +2.9 %/yr)

!Narrow moat 44/100

!Evidence only low, so the estimate is less certain

!Weak on future: 23 out of 100

!Weak on past: 27 out of 100

For context

·7.37% dividend yield

Evidence: Low Range HK$6.35 – HK$10.13

Fair value as of: Aug 30, 2026

From 24 valuation models · updated 7 days ago

Fair value updated Aug 30, 2026, revised from HK$8.23 to HK$8.24 (+0.1%) since Aug 13, 2026. Share price −3.5% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

The price is below even our cautious bear case (HK$6.35). The market is more pessimistic than our downside scenario.
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 30, 2026.

How to read this chart

60‑month range HK$3.10 – HK$17.01 · fair‑value band HK$6.35 – HK$10.13 · the HK$3.27 price screens below the HK$8.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 30, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shandong Weigao Group Medical Polymer Co Ltd (1066) currently trades at HK$3.27, while our model-based Fair Value estimate is HK$8.24, implying the stock looks roughly 60.4% undervalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of HK$10.70 per share, and 24 of the 24 models we run sit above the HK$3.27 price. Bear case: the Asset-Based group reads lowest at HK$3.63, and 0 of the 24 models stay below the price. Evidence for this calculation is low.

Over the trailing twelve months, Shandong Weigao Group Medical Polymer Co Ltd generated revenue of HK$13.4B at a net margin of 12.0%. Revenue grew 4.5% year over year. It earns a return on equity of 6.7%. The balance sheet holds a net cash position of HK$3.0B. Fundamentals as of Aug 30, 2026

Our scenario range runs from HK$6.35 (bear case) to HK$10.13 (bull case); at HK$3.27, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −46% fair-value upside, at 152%, 1066 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence

Highest evidence

FCF DCF HK$6.18 HK$10.70 HK$18.81 77

Growth DCF HK$6.11 HK$10.17 HK$17.21 76

Residual Income HK$4.36 HK$4.56 HK$4.80 76

All 24 models by family

DCF Models

FCF DCF HK$6.18 HK$10.70 HK$18.81 77

Owner Earnings HK$6.33 HK$10.97 HK$19.31 74

5Y Revenue Exit HK$5.03 HK$8.00 HK$12.06 72

5Y EBITDA Exit HK$6.71 HK$11.53 HK$17.70 74

5Y P/E Exit HK$6.48 HK$11.04 HK$16.38 70

10Y Revenue Exit HK$5.25 HK$8.24 HK$12.89 66

10Y EBITDA Exit HK$6.49 HK$10.86 HK$17.72 67

10Y P/E Exit HK$6.34 HK$10.50 HK$16.59 62

Earnings-Based

Graham-Dodd HK$2.46 HK$12.36 HK$17.06 64

Lynch FV HK$3.35 HK$4.78 HK$6.22 61

PEG = 1.0 HK$3.35 HK$4.78 HK$6.22 57

EPV HK$3.99 HK$4.48 HK$4.91 74

Multiples

P/E Multiple HK$5.98 HK$7.97 HK$9.97 63

P/S Multiple HK$4.62 HK$6.16 HK$7.70 58

P/B Multiple HK$4.62 HK$6.16 HK$7.70 55

EV/EBIT HK$5.91 HK$7.53 HK$9.16 66

EV/EBITDA HK$7.38 HK$9.50 HK$11.61 67

EV/Revenue HK$4.52 HK$6.01 HK$7.50 54

Asset-Based

NCAV (Graham) HK$2.71 HK$3.63 HK$5.42 54

Growth DCF

Growth DCF HK$6.11 HK$10.17 HK$17.21 76

Rev-Margin DCF HK$5.03 HK$7.93 HK$11.78 72

Economic Profit

Residual Income HK$4.36 HK$4.56 HK$4.80 76

ROIC Compounder HK$3.99 HK$4.48 HK$4.91 72

Growth Earnings

Growth-Adj P/E HK$5.23 HK$7.47 HK$9.72 67

Widest divergence: DCF Models (HK$10.70) versus Asset-Based (HK$3.63). Highest evidence: FCF DCF (77).

Notify me when 1066 reaches fair value

Put 1066 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 8.1 as of Jul 2, 2026

P/S ratio 0.98 P/E × margin

EPS (TTM) HK$0.2200 price ÷ EPS = P/E 8.1

Dividend yield 7.4% payout 109%

Net margin 12.0% FY2025

Return on equity 6.7% TTM

More key figures

Profitability

Return on assets (EBIT) 7.2% avg 5y

Operating margin 9.9% TTM

Growth

Revenue (TTM) HK$13.4B TTM

Revenue growth (YoY) +4.5% 3y avg −0.6%

EPS growth (YoY) −38.1%

Balance sheet & cash flow

Free cash flow HK$1.7B FY2025

Net cash HK$3.0B FY2025

Figures from reported company fundamentals · as of Aug 30, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 61/100

Of which business quality 61 · Market factors (momentum, volatility) 30

Profitability 36

Margins and returns on capital today

Quality Growth 28

Are margins and returns improving?

Cashflow 64

Earnings quality: real cash, not paper profit

Fin. Strength 80

Balance sheet, leverage, solvency risk

Investment 82

Disciplined investing over empire-building

Low Volatility 76

Calm price path (market factor)

Momentum 16

Price trend over the last 3–12 months (market factor)

52W Momentum 3

Distance to the 52-week high (market factor)

Net Issuance 82

Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Full company description

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, wholesale, and sale of medical devices in the People's Republic of China and internationally. It operates through Medical Device Products, Orthopedic Products, Pharma Packaging Products, Interventional Products, Blood Management Products, and Others segments. The company offers medical device products, including safe infusion, clinical nursing, perioperative, endocrine, urinary, rehabilitation system, and extracorporeal circulation solutions; pharma packaging products comprising prefilled drug delivery system, pharmaceutical packaging consumables, and automatic drug delivery systems; and orthopedic products that include spine, joint, trauma, sports medicine, bone repair material, and spinal endoscope products, as well as orthopedic devices, PRP treatment consumables, and negative pressure drainage consumables. It also provides interventional products, such as tumor, vascular, and nursing interventions, as well as blood management products, including whole blood collection consumables and blood transfusion equipment. In addition, the company manufactures and sells medical PVC granules, plastic packing bags, and carton boxes; manufacture and sale of medical polymer materials and products; injection puncture instruments; computer technical services; and X-ray based irradiation machines. Further, it provides finance leasing, factoring, and consulting services. The company was founded in 1988 and is based in Weihai, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shandong Weigao Group Medical Polymer Co Ltd reported revenue of 13.4B CNY in FY2025 versus 13.2B CNY in FY2021, a compound +0.4%/yr. Reported net income was 1.6B CNY in FY2025, compounding −8.3%/yr from FY2021.

Growth Quality 69/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Latest Revenue (FY 2025)

HK$13.4B

Latest YoY

+2.3%

Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

−0.6%

Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+2.9%

Avg. revenue growth/yr (23Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.

+18.3%

Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.

+2.3% · in HKD

Earnings growth per share plus dividend yield: the value created per share and year.

Earnings growth per share−5.1%

Dividend yield7.4%

Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −5.1% vs 10Y 3.7%, flattening

Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19.6% (2020) → 12.7% (2025) · falling

Worst earnings drop89% (2013) · in HKD

Revenue +0.4%/yr

FY21 13.2B CNY

FY22 13.6B CNY

FY23 13.2B CNY

FY24 13.1B CNY

FY25 13.4B CNY

Net income −8.3%/yr

FY21 2.3B CNY

FY22 2.8B CNY

FY23 2.0B CNY

FY24 2.1B CNY

FY25 1.6B CNY

Character of growth · EPS growth decomposed (2014-2025) +6.1 % p.a.

Revenue per share +9.1 %

of which total revenue +9.2 % · buybacks/dilution −0.1 %

EBIT margin −4.1 %

Tax rate −0.1 %

Residual (interest, one-offs) +1.5 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

Watch 1066: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shandong Weigao Group Medical Polymer Co Ltd · Fair Value
HK$8.24 +60%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/1066.HK" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shandong Weigao Group Medical Polymer Co Ltd · Fair Value</span><br><b style="font-size:20px">HK$8.24</b> <span style="color:#7BB290;font-weight:700;font-size:14px">+60%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shandong Weigao Group Medical Polymer Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1066.HK

Peer Group

Medical Instruments & Supplies · 194 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 61 · Above median

Fair Value upside +152% · Top 25%

Return on equity (TTM) 7% · Above median

Return on assets 3% · Below median

Net margin (TTM) 12% · Above median

Operating margin (TTM) 10% · Below median

Revenue growth 5% · Below median

Dividend yield (TTM) 7.4% · Top 25%

Debt / equity 0.18× · Higher than median

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 8.1× · Cheaper than 75% of peers

P/B 0.60× · Cheaper than 75% of peers

P/S (TTM) 1.08× · Cheaper than median

P/FCF 1.1× · Cheaper than median

EV/EBITDA 3.6× · Cheaper than 75% of peers

PEG 0.69× · Cheaper than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

This stock

Sector peers

VALUE100 · sector 0

FUTURE23 · sector 29

PAST27 · sector 26

HEALTH91 · sector 96

DIVIDEND100 · sector 30

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Aug 30, 2026).

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$366.70	$150.04	−59%
EssilorLuxottica Société anonyme EL	€160.35	€94.93	−41%
Medline Inc MDLN	$36.59	$30.15	−18%
Becton, Dickinson and Company BDX	$187.12	$100.46	−46%
Alcon Inc ALC	$70.50	$39.78	−44%
ResMed Inc RMD	A$33.19	A$26.23	−21%
West Pharmaceutical Services, Inc WST	$337.47	$141.58	−58%
Sartorius Stedim Biotech S.A DIM	€197.70	€48.88	−75%
Straumann Holding STMN	CHF 97.38	CHF 47.31	−51%
Sartorius Aktiengesellschaft SRT3	€237.20	€63.30	−73%

Compare Shandong Weigao Group Medical Polymer Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Shandong Weigao Group Medical Polymer Co Ltd (1066) overvalued or undervalued?

As of Aug 30, 2026, our model estimates a fair value of HK$8.24 versus a price of HK$3.27, about +152% upside (undervalued).

What is the fair value of 1066?

Our model-based fair value for Shandong Weigao Group Medical Polymer Co Ltd is HK$8.24 (as of Aug 30, 2026), built from audited fundamentals. The current price: HK$3.27.

What is the quality score of 1066?

Shandong Weigao Group Medical Polymer Co Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shandong Weigao Group Medical Polymer Co Ltd (1066)?

Our model-based price target is the fair value of HK$8.24 (as of Aug 30, 2026) from 24 valuation models. Cautious scenario HK$6.35, optimistic scenario HK$10.13. It is a calculation from audited fundamentals, not an analyst target.

What is the Shandong Weigao Group Medical Polymer Co Ltd stock forecast for 2026?

Our models put fair value at HK$8.24, about +152% upside versus a price of HK$3.27 (undervalued). Cautious scenario HK$6.35, optimistic scenario HK$10.13. The calculation is refreshed regularly with new filings.

What is the revenue of Shandong Weigao Group Medical Polymer Co Ltd (1066)?

Shandong Weigao Group Medical Polymer Co Ltd reported trailing-twelve-month revenue of about HK$13.4B (latest available figure, as of Aug 30, 2026).

What is the net profit margin of 1066?

The net profit margin of Shandong Weigao Group Medical Polymer Co Ltd is about 12.0%, meaning it keeps roughly 12.0% of revenue as net income. Based on the latest reported figures.

Does Shandong Weigao Group Medical Polymer Co Ltd pay a dividend?

Shandong Weigao Group Medical Polymer Co Ltd currently shows a dividend yield of about 7.37% relative to its recent price (as of Aug 30, 2026).

Free · no account needed

Watch Shandong Weigao Group Medical Polymer Co Ltd in the live analysis

One click puts Shandong Weigao Group Medical Polymer Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.